Skip to main content Back to Top
Advertisement

12/11/2024

Anticoagulant Citrate Dextrose Formula A (ACD-A)

Products Affected - Description

    • Anticoagulant Citrate Dextrose Formula A solution, Fresenius Kabi, 1,000 mL bag, NDC 00942-0641-04

Reason for the Shortage

    • Fresenius Kabi has ACD-A solution on shortage due to manufacturing delays. The product is manufactured by Baxter at their North Cove plant that was damaged by a hurricane.

Available Products

    • There are no presentations available

Estimated Resupply Dates

    • Fresenius Kabi has ACD-A 1,000 mL bags on back order and the company estimates a release date of early-January 2025.

Updated

Created December 11, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.

ADVERTISEMENT